arrow
K

Kimmo Porkka

university of helsinki
H指数:69
被引数:2.4万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

RUNX1 aberrations in blast-phase chronic myeloid leukaemia induce the RNA-binding protein SPATS2L, which promotes growth, survival and stress granule assembly

RUNX1异常在原始细胞期慢性髓系白血病中诱导RNA结合蛋白SPATS2L,进而促进生长、存活和应激颗粒组装

Leukemia
IF13.4
2026-10-090
OAAI
Assessing Overall Survival Benefits in Advanced Cancers: The Role of External Comparator Cohort Studies with Real-World Data

评估晚期癌症总生存获益:外部对照队列研究结合真实世界数据的作用

2026-02-110
OAAI
Different features of acute myeloid leukemia stem cell quantification in intensively treated patients

高强度治疗患者中急性髓系白血病干细胞定量测定的不同特征。Haematologica

2025-12-012
OA
Computational measurable residual disease assessment in acute myeloid leukemia: a retrospective validation in the HOVON-SAKK-132 trial

急性髓系白血病中的计算性微小残留病评估:一项在HOVON-SAKK-132试验中的回顾性验证

Leukemia
IF13.4
2025-09-030
OAAI
Integrating Computational Cytomorphological Analysis of Bone Marrow Smears and Clinical Data for Predicting Response to Venetoclax and Hypomethylating Agents in AML

整合骨髓涂片的计算细胞形态学分析与临床数据,以预测AML对Venetoclax和表观遗传学药物的反应

BLOOD
IF23.1
2024-11-050
PRE
Computational Cytomorphological Analyses Identifies Bone Marrow Erythroblast Proportion As a Biomarker of Treatment-Free Remission in CML

计算细胞形态学分析将骨髓红细胞比例鉴定为CML治疗无复发的生物标志物

BLOOD
IF23.1
2024-11-050
PRE
Single-cell transcriptomes identify patient-tailored therapies for selective co-inhibition of cancer clones

单细胞转录组鉴定针对癌症克隆的选择性共抑制的患者定制疗法

2024-10-030
OAAI
Acquired Multidrug Resistance in AML Is Caused by Low Apoptotic Priming in Relapsed Myeloblasts
2024-05-012
OA
Integrated drug profiling and CRISPR screening identify BCR::ABL1-independent vulnerabilities in chronic myeloid leukemia

综合药物分析和CRISPR筛选确定BCR:: 慢性粒细胞白血病的ABL1-independent脆弱性

2024-05-012
OAAI
Long-term follow-up of VIALE-A: Venetoclax and azacitidine in chemotherapy-ineligible untreated acute myeloid leukemia
2024-02-1132
PRE
Phase Ib study of sabatolimab (MBG453), a novel immunotherapy targeting TIM-3 antibody, in combination with decitabine or azacitidine in high- or very high-risk myelodysplastic syndromes

针对TIM-3抗体的新型免疫疗法sabatolimab (MBG453) 与地西他滨或阿扎胞苷联合治疗高危或极高危骨髓增生异常综合征的Ib期研究

2023-11-2212
OAAI
Identification of DHX40 as a candidate susceptibility gene for colorectal and hematological neoplasia

鉴定DHX40作为结直肠和血液肿瘤的候选易感基因

LEUKEMIA
IF13.4
2023-09-111
OAAI
A first-in-human phase 1 study of LY3410738, a covalent inhibitor of mutant IDH, in advanced myeloid malignancies
2023-04-141
PRE